tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta price target raised to $19 from $18 at RBC Capital
The FlySarepta price target raised to $19 from $18 at RBC Capital
2d ago
SRPT
Deutsche ups Sarepta target, says 35% stock rally overdone
PremiumThe Fly
Deutsche ups Sarepta target, says 35% stock rally overdone
14d ago
SRPT
Sarepta price target raised to $35 from $29 at Wedbush
PremiumThe Fly
Sarepta price target raised to $35 from $29 at Wedbush
14d ago
SRPT
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
PremiumRatings
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
14d ago
SRPT
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
PremiumRatings
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
14d ago
SRPT
Sarepta price target raised to $13 from $9 at Citi
PremiumThe FlySarepta price target raised to $13 from $9 at Citi
14d ago
SRPT
Sarepta price target raised to $25 from $20 at Morgan Stanley
Premium
The Fly
Sarepta price target raised to $25 from $20 at Morgan Stanley
14d ago
SRPT
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
Premium
The Fly
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
15d ago
GM
AMD
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
PremiumThe Fly
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
15d ago
SRPT
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
PremiumThe Fly
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
15d ago
SRPT
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
PremiumThe Fly
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
15d ago
SRPT
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
PremiumThe Fly
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
20d ago
SLDB
SRPT
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
PremiumThe FlySarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
21d ago
SRPT
Sarepta provides regulatory update on Amondys 45, Vyondys 53
Premium
The Fly
Sarepta provides regulatory update on Amondys 45, Vyondys 53
21d ago
SRPT
Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
Premium
The Fly
Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
24d ago
SRPT
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
PremiumWeekend Updates
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
26d ago
WBD
AXON
Sarepta price target raised to $31 from $26 at Mizuho
PremiumThe Fly
Sarepta price target raised to $31 from $26 at Mizuho
27d ago
SRPT
Sarepta price target raised to $9 from $8 at Citi
PremiumThe Fly
Sarepta price target raised to $9 from $8 at Citi
30d ago
SRPT
Controversial Prasad leaving FDA, NYT reports
PremiumThe Fly
Controversial Prasad leaving FDA, NYT reports
1M ago
AZN
BMY
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
PremiumCompany AnnouncementsSarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
1M ago
SRPT
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
Premium
Company Announcements
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
1M ago
SRPT
Sarepta price target lowered to $29 from $34 at Wedbush
Premium
The Fly
Sarepta price target lowered to $29 from $34 at Wedbush
1M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >